News

Gunagratinib (ICP-192), a potential therapeutic option for patients with cholangiocarcinoma, has been granted an orphan drug designation by the FDA.

The FDA granted a priority review for a Biologics License Application (BLA) to bastilimab for the treatment of recurrent or metastatic cervical cancer.

The FDA approved avapritinib (Ayvakit) for the treatment of adults with advanced systemic mastocytosis (AdvSM), including those with mast cell leukemia (MCL), aggressive systemic mastocytosism (ASM), or systemic mastocytosis with an associated hematological neoplasm (SM-AHN).

After hearing about the difficulties a transgender man faced in receiving a cancer diagnosis, Kelly S. Haviland, PhD, FNP-BC, found her calling.

Amanpour, who is CNN's chief international anchor, announced her diagnosis live on-air, while advocating for cancer screening, too.

The FDA approved injectable technetium Tc 99m tilmanocept (Lymphoseek), a radiopharmaceutical agent that targets lymphatic mapping and guiding for sentinel lymph node biopsies (SLNB), for use in pediatric patients with melanoma, rhabdomyosarcoma, and other solid tumors.

This year, there were many takeaways from the American Society of Clinical Oncology Annual Meeting that oncology nurses can incorporate into their practice.

Getting an accurate history – and doing so in a comfortable and non-judgmental way – can improve cancer care for LGBTQ patients.

The FDA has accepted the biologics license application for a proposed biosimilar for pegfilgrastim, which had been developed by Lupin Limited.

Cultural competence, multidisciplinary efforts with diverse faculty, and high-risk screening programs could help to address critical gaps and cancer disparities.

Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from May 2021.

Smoking cessation has major benefits – even after a patient received a diagnosis of cancer.

Age was associated with overall survival and the time to Richter transformation in adolescent and young adult patients with chronic lymphocytic leukemia, according to findings from a single-institutional, retrospective study.

Public health efforts must address new methods of cancer screening, an expert says.

The FDA has granted priority review to the biologics license application for ciltacabtagene autoleucel for the treatment of patients with relapsed/refractory multiple myeloma.

The FDA has approved piflufolastat F 18 injection, a prostate-specific membrane antigen–targeted positron emission tomography imaging agent to identify suspected metastasis or recurrence of prostate cancer.

From medical information cards to visual cues, a nurse navigator offers advice on ensuring quality care for patients who do not speak English.

The FDA has accepted a biologics license application for ublituximab in combination with umbralisib in the treatment of patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

The FDA has accepted a new drug application for maribavir for the treatment of post-transplant recipients with cytomegalovirus infection who are refractory and/or resistant to previous anti-CMV treatment.

Oncology advanced practice registered nurses are key players in the mitigation, preparation, response, and recovery of a public health disaster, such as the COVID-19 pandemic.

The pandemic drastically increased the use of telehealth in cancer care. But even as COVID-19 restrictions are decreasing, virtual care is here to stay, says 1 nurse.

This is the first targeted therapy regimen approved for this patient population.

The FDA approved adjuvant nivolumab for the treatment of patients with resected esophageal or gastroesophageal (GEJ) cancer who have previously had neoadjuvant chemoradiation treatment.

When clinicians had a standard tool to refer patients to palliative care, quality of care and patient referrals were both improved, according to a recent study.

Better prognostic understanding led to earlier use of palliative care and more DNRs in patients with late-stage cancer.

The United States Preventative Services Task Force now recommends colorectal cancer screening to start at 45 years old.

There is no fall risk assessment that is specific to oncology, but one could be helpful in preventing accidents.

The FDA has approved pegcetacoplan (Empaveli) for the treatment of adults with paroxysmal nocturnal hemoglobinuria who are treatment naïve and those who are switching from the C5 inhibitors eculizumab (Soliris) and ravulizumab (Ultomiris).